TITLE

Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Tablets (Complera)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
September 2011
SOURCE
Internal Medicine Alert;9/15/2011, Vol. 33 Issue 17, p133
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the emtricitabine/rilpivirine/tenofovir disoproxil fumarate drug combination known as Complera for the treatment of HIV-1 infection, developed by Gilead Sciences Inc.
ACCESSION #
66179454

 

Related Articles

  • The New Little Blue Sex Pill. HEYWOOD, TODD // Between the Lines (10807551);5/22/2014, Issue 2221, p5 

    The article offers information on an anti-HIV drug that was developed by Gilead called Truvada.

  • Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide Meets Primary 48-Week Objective in Phase 3 Study.  // Clinical Infectious Diseases;11/15/2015, Vol. 61 Issue 10, pii 

    The article discusses a phase 3 study by the biotechnology firm Gilead Sciences Inc. to evaluate the efficacy of a fixed-dose combination of emtricitabine and tenofovir alafenamide for the treatment of HIV-1 infection, which showed virologic suppression rate same as tenofovir disoproxil fumarate.

  • New quad pill for HIV. Tanzi, Maria G. // Pharmacy Today;Oct2012, Vol. 18 Issue 10, p45 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the tablet,Stribild from Gilead Sciences Inc., that contains elvitegravir, cohicistat, emtricitabine, tenofovir, used for the management of HIV-1 infection in the U.S. It mentions that the approval of the pills are...

  • Potential HIV prophylaxis enters Canadian pilot trial. Lawson, Jack // CMAJ: Canadian Medical Association Journal;5/13/2014, Vol. 186 Issue 8, pE234 

    The article focuses on the clinical trials of Truvada for the treatment of HIV that will begin in Canada in March 2015. Topics covered include the failure of Gilead Sciences Canada, Inc. to submit an application to Health Canada for the use of Truvada as prophylaxis, an overview of the pilot...

  • Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU. Deeks, Emma; Lyseng-Williamson, Katherine; Plosker, Greg // Drugs & Therapy Perspectives;Jan2017, Vol. 33 Issue 1, p8 

    The fixed-dose combination of emtricitabine/tenofovir disoproxil fumarate (tenofovir DF) [Truvada] is approved in the EU for pre-exposure prophylaxis, in conjunction with safer sex practices, to reduce the risk of sexually-acquired HIV-1 infection in adults at high risk. Once-daily...

  • Optimizing Initial Therapy for HIV Infection. Hull, Mark W.; Montaner, Julio S. G. // Journal of Infectious Diseases;10/15/2011, Vol. 204 Issue 8, p1154 

    An introduction is presented in which the author discusses the use of efavirenz and boosted atazanavir in combination with tenofovir/ emtricitabine as initial therapy for treatment against HIV infection.

  • IS THIS THE NEW CONDOM? MURPHY, TIM // Out;Oct2013, Vol. 22 Issue 3, p70 

    The article focuses on Truvada, a pre-exposure HIV prophylaxis (PrEP), from biotechnology company Gilead. The pill has been approved by the U.S. Food and Drug Administration and is covered by health insurers, making reference to findings from a 2010 study of HIV-negative gay men called iPrex. It...

  • Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla(r) in Pivotal Phase 3 Study.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article offers information on an announcement made by Gilead Sciences Inc., biopharmaceutical company regarding its study related to the clinical trials of Quad, for treatment against HIV-1 infection which revealed that drug is equally effective as Atripla, most-prescribed HIV treatment...

  • THE HIV YEAR IN REVIEW. ANDERSON-MINSHALL, DIANE // Advocate;Dec2014/Jan2015, Issue 1076, p45 

    A timeline is presented of HIV- and AIDS-related events in 2014 including German scientists who reported extracts from the geranium plant Pelargonium sidoides can block HIV from entering human cells, University of Missouri researchers who reported a molecule in soy sauce, EFdA, could be used to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics